Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.
Pharvaris N.V. (PHVS) news centers on its progress as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema. Company updates frequently highlight clinical milestones for its lead candidate deucrictibant, including pivotal Phase 3 programs in hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
Investors following PHVS news can expect detailed announcements on clinical trial results and timelines. Recent releases describe RAPIDe-3, a pivotal global Phase 3 study of deucrictibant immediate-release capsule for on-demand treatment of HAE attacks, which met its primary endpoint and all secondary efficacy endpoints with statistical significance and was reported as well tolerated. Other updates cover CHAPTER-3 and CHAPTER-4, Phase 3 studies of the extended-release tablet for long-term prophylaxis of HAE attacks, and CHAPTER-1 Phase 2 data showing sustained reductions in attack rates over long-term treatment.
Pharvaris news also includes information on the CREAATE Phase 3 study in AAE-C1INH, presentations of deucrictibant data at major medical congresses, and summaries of biomarker work such as the kinin assay being clinically validated to characterize bradykinin-mediated angioedema. Financial and corporate updates, including quarterly results, cash runway commentary, and details of public offerings of ordinary shares and pre-funded warrants, are furnished through press releases and Form 6-K filings.
For readers tracking PHVS, this news stream provides insight into the advancement of deucrictibant’s prophylactic and on-demand indications, regulatory filing plans such as the preparation of marketing authorization applications, and the company’s broader efforts in bradykinin-mediated diseases.
Pharvaris (Nasdaq: PHVS) reported Q4 and full-year 2025 results and provided a business update on deucrictibant clinical programs. Key milestones: CHAPTER-3 enrollment complete with topline data expected in 3Q2026, RAPIDe-3 pivotal success supports an on-track NDA submission in 1H2026, and cash of €292 million at year-end.
Company continues enrollment in CREAATE and long-term CHAPTER-4 extension while highlighting RAPIDe-3 median onset and resolution times versus placebo.
Pharvaris (Nasdaq: PHVS) announced publication of two Phase 2 trials in The Lancet Haematology showing deucrictibant, an oral bradykinin B2 receptor antagonist, had statistically significant efficacy and was well tolerated for both prophylaxis (CHAPTER-1) and on-demand treatment (RAPIDe-1) of hereditary angioedema (HAE) attacks.
The company said CHAPTER-1 showed reduced attack occurrence and improved quality of life, while RAPIDe-1 showed reduced attack severity and faster symptom relief; Phase 3 topline from CHAPTER-3 is expected in Q3 2026.
Pharvaris (Nasdaq: PHVS) published a peer-reviewed study validating patient-reported outcome (PRO) instruments for on-demand hereditary angioedema (HAE) treatment endpoints.
The non-interventional, mixed-methods study found PGI and AMRA tools reliable and sensitive, identified End of Progression™ as earliest meaningful endpoint, and aligned PGI-C "a little better" with AMRA-3 ≥20%, informing Phase 3 RAPIDe-3 endpoint hierarchy.
Pharvaris (Nasdaq: PHVS) presented Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 data at AAAAI 2026 supporting deucrictibant for on‑demand and prophylactic treatment of bradykinin‑mediated angioedema.
RAPIDe-3 met the primary and all 11 secondary endpoints: median onset of symptom relief 1.28 hours and complete resolution 11.95 hours versus much longer placebo times. CHAPTER-1 OLE showed mean attack rate fell from 2.18 to 0.12 attacks/month and roughly half of participants were attack free; no treatment‑related serious adverse events reported.
Pharvaris (Nasdaq: PHVS) will present six abstracts, including three Featured Posters, at the AAAAI 2026 Annual Meeting in Philadelphia from February 27–March 2, 2026. Key topics include pivotal Phase 3 RAPIDe-3 on-demand data, final CHAPTER-1 open-label results, and extended-release pharmacokinetics for CHAPTER-3.
Topline CHAPTER-3 results are anticipated in Q3 2026. Posters and slides will be posted on the company's investor site at the start of each presentation.
Pharvaris (NASDAQ: PHVS) outlined 2026 priorities focused on late‑stage development and regulatory filings for oral deucrictibant for bradykinin‑mediated angioedema. Key milestones: topline CHAPTER‑3 prophylaxis data expected 3Q2026; NDA preparation for on‑demand HAE treatment targeted for filing in 1H2026 based on RAPIDe‑3 and RAPIDe‑2; RAPIDe‑3 met its primary and all secondary endpoints with median onset of symptom relief of 1.28 hours (p<0.0001). CREAATE pivotal study in AAE‑C1INH is enrolling; CHAPTER‑4 long‑term extension is ongoing; CHAPTER‑1 open‑label data showed mean on‑treatment monthly attack rate of 0.12. Corporate runway is estimated into 1H2027, and Pharvaris was added to the Nasdaq Biotechnology Index in Dec 2025.
Pharvaris (NASDAQ: PHVS) reported positive topline results from the RAPIDe-3 pivotal Phase 3 study of oral deucrictibant IR 20 mg for on-demand treatment of hereditary angioedema (HAE) attacks.
The primary endpoint was met: median time to onset of symptom relief was 1.28 hours vs >12 hours for placebo (p<0.0001). All 11 secondary endpoints were significant, including End of Progression™ 17.47 minutes/b vs 228.67 minutes and median time to complete symptom resolution Deucrictibant was well tolerated with no treatment-related serious adverse events; NDA filings are planned starting H1 2026.
Pharvaris (Nasdaq: PHVS) reported Q3 2025 results and a business update highlighting pivotal Phase 3 programs for deucrictibant. RAPIDe-3 (on-demand HAE, 20 mg immediate-release) reached ~120 participants and topline data are expected in 4Q2025. CHAPTER-3 (prophylaxis, 40 mg extended-release) enrollment is progressing with topline data anticipated in 2H2026. Pharvaris initiated CREAATE (AAE-C1INH pivotal study) and reported Phase 2 CHAPTER-1 OLE on-treatment attack rate of 0.12. Corporate financing included a public offering with proceeds of approximately $201 million. Cash and cash equivalents were €329 million as of September 30, 2025, providing runway into H1 2027. Q3 operating metrics: R&D €29.8M, G&A €9.8M, net loss €37.1M (loss per share €0.60).
Pharvaris (Nasdaq: PHVS) presented clinical and biomarker data at ACAAI 2025 highlighting deucrictibant's long-term safety, sustained efficacy, and a validated kinin assay.
Key data: open-label CHAPTER-1 extension showed treatment for up to ~34 months with mean attacks reduced from 2.18 to 0.12 attacks/month and an average 92.4% attack reduction; RAPIDe-2 Part A reported a median time-to-onset of symptom relief of 1.1 hours and median time-to-resolution of 10.6 hours with 89.2% of attacks resolved at 24 hours after a single dose.
The company also reported a clinically validated plasma kinin biomarker assay and reiterated expected pivotal readouts: CHAPTER-3 in H2 2026 and RAPIDe-3 in Q4 2025.
Pharvaris (Nasdaq: PHVS) announced acceptance of 2 oral and 6 poster presentations at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025.
Presentations focus on clinical data for oral deucrictibant in hereditary angioedema (prophylaxis and on‑demand treatment), biomarker assay validation, long‑term safety and efficacy (CHAPTER‑1 and RAPIDe‑2), and pharmacokinetics of an extended‑release tablet. Slides and posters will be posted on the company's investor website at presentation start times.